{"id":"ketamine-1st-phase","safety":{"commonSideEffects":[{"rate":null,"effect":"Dissociation"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Increased blood pressure"},{"rate":null,"effect":"Sedation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ketamine binds to the phencyclidine binding site within the NMDA receptor ion channel, blocking the flow of ions and preventing excitatory glutamate neurotransmission. This mechanism produces rapid-onset dissociative and analgesic effects. In psychiatric applications, particularly for treatment-resistant depression, ketamine's effects are thought to involve downstream neuroplasticity changes and increased brain-derived neurotrophic factor (BDNF) signaling.","oneSentence":"Ketamine is a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that blocks glutamate signaling in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:51:02.071Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment-resistant depression"},{"name":"Acute suicidal ideation and behavior"},{"name":"Chronic pain conditions"}]},"trialDetails":[{"nctId":"NCT05004896","phase":"PHASE2","title":"Ketamine for Treatment-Resistant Bipolar Disorder","status":"COMPLETED","sponsor":"Joshua Rosenblat","startDate":"2022-07-04","conditions":"Bipolar Disorder, Bipolar Depression, Bipolar I Disorder","enrollment":71},{"nctId":"NCT07422519","phase":"NA","title":"Virtual Reality-Based Mindfulness as an Adjunct to Treatment as Usual in Treatment-Resistant Depression","status":"RECRUITING","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2025-09-18","conditions":"Depression - Major Depressive Disorder, Depression Disorder, Depression Chronic","enrollment":30},{"nctId":"NCT02299440","phase":"PHASE3","title":"Effects of Ketamine in the Acute Phase of Suicidal Ideation","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2015-04","conditions":"Suicidal Ideation","enrollment":156},{"nctId":"NCT06431386","phase":"NA","title":"Behavioural Activation Therapy and Esketamine for Resistant Depression","status":"TERMINATED","sponsor":"The Royal's Institute of Mental Health Research","startDate":"2024-06-11","conditions":"Depressive Disorder, Treatment-Resistant, Depressive Disorder, Major, Bipolar Disorder","enrollment":6},{"nctId":"NCT06816433","phase":"PHASE2","title":"Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002","status":"NOT_YET_RECRUITING","sponsor":"Global Coalition for Adaptive Research","startDate":"2025-11","conditions":"Post Traumatic Stress Disorder","enrollment":200},{"nctId":"NCT06658132","phase":"NA","title":"A General Anesthesia Regimen for DBS Surgery in Patients With PD","status":"COMPLETED","sponsor":"RenJi Hospital","startDate":"2024-10-29","conditions":"Parkinson's Disease (PD)","enrollment":20},{"nctId":"NCT02493868","phase":"PHASE3","title":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-10-01","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":719},{"nctId":"NCT02497287","phase":"PHASE3","title":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-09-30","conditions":"Treatment-resistant Depression","enrollment":802},{"nctId":"NCT02422186","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-20","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":139},{"nctId":"NCT06013345","phase":"PHASE3","title":"COnventional Vs. Optimised PERiprocedural Analgosedation Vs. Total IntraVEnous Anaesthesia for Pulsed-Field Ablation (COOPERATIVE-PFA)","status":"COMPLETED","sponsor":"Charles University, Czech Republic","startDate":"2023-10-25","conditions":"Atrial Fibrillation","enrollment":127},{"nctId":"NCT06070766","phase":"","title":"RIVER At Home Ketamine Protocols","status":"RECRUITING","sponsor":"RIVER Foundation","startDate":"2023-10-01","conditions":"Chronic Condition, Chronic Pain, Chronic Disease","enrollment":50000},{"nctId":"NCT06543563","phase":"NA","title":"Esketamine in Microelectrode Recording-guided Subthalamic Deep-Brain Stimulation for Parkinson's Disease","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2024-08-09","conditions":"PD - Parkinson's Disease, Deep Brain Stimulation, Esketamine","enrollment":102},{"nctId":"NCT06103760","phase":"PHASE4","title":"Positioning of Esketamine Treatment in the Real-world Management of Depression","status":"RECRUITING","sponsor":"Royal North Shore Hospital","startDate":"2023-10-31","conditions":"Major Depressive Disorder","enrollment":162},{"nctId":"NCT02501941","phase":"PHASE1","title":"Spreading Depolarization and Ketamine Suppression","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2015-07","conditions":"Cortical Spreading Depolarization, Cortical Spreading Depression, Subarachoid Hemorrhage","enrollment":10},{"nctId":"NCT02644629","phase":"PHASE4","title":"Intra-nasal vs. Intra-venous Ketamine Administration","status":"COMPLETED","sponsor":"Shalvata Mental Health Center","startDate":"2016-04","conditions":"Major Depressive Disorder","enrollment":45},{"nctId":"NCT03644719","phase":"NA","title":"Effectiveness of a Brief Cognitive and Behavioral Skills Program on Stage Transitions for Chronic Ketamine Abusers","status":"COMPLETED","sponsor":"National Taiwan University","startDate":"2014-08-19","conditions":"Substance Use Disorders","enrollment":409},{"nctId":"NCT02094898","phase":"PHASE2","title":"Ketamine for Depression and Suicide Risk","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2014-09","conditions":"Depression, Suicide","enrollment":12},{"nctId":"NCT01833897","phase":"PHASE4","title":"NMDA Antagonists in Bipolar Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2013-03","conditions":"Bipolar Disorder","enrollment":8},{"nctId":"NCT01809340","phase":"PHASE2","title":"The Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced Symptoms Response in Subjects With Depression","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-06","conditions":"Depressive Disorder","enrollment":29},{"nctId":"NCT01243801","phase":"PHASE4","title":"Prevention of Persistent Postsurgical Pain After Thoracotomy","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2008-09","conditions":"Persistent Pain, Postoperative Hyperalgesia","enrollment":104}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ketalar"],"phase":"marketed","status":"active","brandName":"Ketamine (1st phase)","genericName":"Ketamine (1st phase)","companyName":"Shalvata Mental Health Center","companyId":"shalvata-mental-health-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ketamine is a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that blocks glutamate signaling in the brain. Used for Treatment-resistant depression, Acute suicidal ideation and behavior, Chronic pain conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}